澳洲成為首個將搖頭丸用於憂鬱症、創傷後壓力症候群(PTSD)的國家
原文報導-美聯社
澳洲成為第一個允許精神科醫生為憂鬱症或創傷後壓力症候群患者開出某些迷幻藥物的國家。
澳洲醫生可以為治療創傷後壓力症候群（PTSD）開出一定劑量的搖頭丸（MDMA）。
該法案於 2 月份宣布，於 7 月 1 日生效。
美國FDA上個月末發布指導草案，指導研究人員設計臨床試驗，測試迷幻藥作為各種醫療狀況的潛在治療方法。
但美國精神病學協會尚未批准在治療中使用致幻劑，並表示 FDA 尚未做出最終決定。
包括美國和澳洲的醫學專家警告，迷幻藥可能會導致幻覺，需要對藥物的功效和迷幻藥的風險程度進行更多研究。
這些藥物在澳洲價格昂貴——每位的治療費約10000澳幣(相當於約6,600 美元)。
【Abstract】
Australia is now the first country to allow psychiatrists to prescribe certain psychedelic substances to patients with depression or post-traumatic stress disorder.
Australian physicians can prescribe doses of MDMA, also known as ecstasy, for PTSD.
which was announced in February but took effect July 1.
The FDA released draft guidance late last month for researchers designing clinical trials testing psychedelic drugs as potential treatments for a variety of medical conditions.
the American Psychiatric Association has not endorsed the use of psychedelics in treatment, noting the FDA has yet to offer a final determination.
And medical experts in the U.S. and elsewhere, Australia included, have cautioned that more research is needed on the drugs’ efficacy and the extent of the risks of psychedelics, which can cause hallucinations.
Plus, the drugs will be expensive in Australia — about $10,000 (roughly $6,600 U.S. dollars) per patient for treatment.
從 APP 打開
X